AKEBIA THERAPEUTICS, INC. Increase (Decrease) in Contract with Customer, Liability
AKEBIA THERAPEUTICS, INC. (AKBA) reported Increase (Decrease) in Contract with Customer, Liability of $3.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-05
- AKEBIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $1.67M, a 61.01% decline year-over-year.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $1.81M, a 46.25% increase year-over-year.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$1.20M.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$1.65M.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2025 was $2.68M.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2024 was $0.00.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2023 was -$3.74M, a 180.32% decline from fiscal 2022.
- AKEBIA THERAPEUTICS, INC. increase (decrease) in contract with customer, liability for fiscal 2022 was $4.65M, a 155.57% increase from fiscal 2021.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $3.49M 10-Q · filed 2026-08-05 | $2.29M derived: sum of 3 quarters · filed 2026-08-05 | $637.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.81M 10-Q · filed 2026-05-07 | $615.00K derived: sum of 2 quarters · filed 2026-05-07 | -$1.04M derived: sum of 3 quarters · filed 2026-05-07 | $3.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$1.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$2.85M derived: sum of 2 quarters · filed 2026-02-26 | $1.44M derived: sum of 3 quarters · filed 2026-08-05 | $2.68M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$1.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $2.64M derived: sum of 2 quarters · filed 2026-08-05 | $3.88M 10-Q · filed 2025-11-10 | $3.88M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $4.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $5.53M 10-Q · filed 2026-08-05 | $5.53M derived: sum of 3 quarters · filed 2026-08-05 | $5.53M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $1.24M 10-Q · filed 2026-05-07 | $1.24M derived: sum of 2 quarters · filed 2026-05-07 | $1.24M derived: sum of 3 quarters · filed 2026-05-07 | $546.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | -$695.00K derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$695.00K derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$695.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $695.00K 10-Q · filed 2025-05-08 | $695.00K derived: sum of 2 quarters · filed 2026-02-26 | $695.00K derived: sum of 3 quarters · filed 2026-02-26 | $695.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | -$3.74M 10-K · filed 2026-02-26 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | -$3.74M 10-Q · filed 2024-11-07 | -$1.26M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.74M 10-Q · filed 2024-08-08 | -$1.26M derived: sum of 3 quarters · filed 2024-08-08 | -$5.05M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$3.74M 10-Q · filed 2024-05-09 | -$1.26M derived: sum of 2 quarters · filed 2024-05-09 | -$5.05M derived: sum of 3 quarters · filed 2024-05-09 | -$32.50M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$1.31M derived: sum of 2 quarters · filed 2024-03-14 | -$28.76M derived: sum of 3 quarters · filed 2024-03-14 | $4.65M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$3.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$31.23M derived: sum of 2 quarters · filed 2023-11-08 | $2.18M 10-Q · filed 2023-11-08 | $904.00K derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$27.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-28 | $5.96M 10-Q · filed 2023-08-28 | $4.69M derived: sum of 3 quarters · filed 2023-08-28 | $19.88M derived: sum of 4 quarters · filed 2023-08-28 |
| 2022-03-31 | $33.42M 10-Q · filed 2023-05-08 | $32.14M derived: sum of 2 quarters · filed 2023-08-28 | $47.33M derived: sum of 3 quarters · filed 2023-08-28 | $38.24M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-12-31 | -$1.28M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | $13.91M derived: sum of 2 quarters · filed 2023-08-28 | $4.83M derived: sum of 3 quarters · filed 2023-08-28 | $1.82M 10-K/A · filed 2023-08-28 |
| 2021-09-30 | $15.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $6.11M derived: sum of 2 quarters · filed 2022-11-03 | $3.10M 10-Q · filed 2022-11-03 | -$8.04M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-06-30 | -$9.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$12.09M 10-Q · filed 2022-08-04 | -$23.23M derived: sum of 3 quarters · filed 2023-08-28 | -$29.60M derived: sum of 4 quarters · filed 2023-08-28 |
| 2021-03-31 | -$3.01M 10-Q · filed 2022-05-09 | -$14.14M derived: sum of 2 quarters · filed 2023-08-28 | -$20.52M derived: sum of 3 quarters · filed 2023-08-28 | -$40.13M derived: sum of 4 quarters · filed 2023-08-28 |
| 2020-12-31 | -$11.13M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28 | -$17.51M derived: sum of 2 quarters · filed 2023-08-28 | -$37.13M derived: sum of 3 quarters · filed 2023-08-28 | -$32.39M 10-K/A · filed 2023-08-28 |
| 2020-09-30 | -$6.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$25.99M derived: sum of 2 quarters · filed 2021-11-04 | -$21.26M 10-Q · filed 2021-11-04 | -$24.34M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$19.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$14.88M 10-Q · filed 2021-08-05 | -$17.96M derived: sum of 3 quarters · filed 2022-03-01 | -$37.80M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $4.74M 10-Q · filed 2021-05-10 | $1.66M derived: sum of 2 quarters · filed 2022-03-01 | -$18.19M derived: sum of 3 quarters · filed 2022-03-01 | -$28.79M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | -$3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$22.92M derived: sum of 2 quarters · filed 2022-03-01 | -$33.52M derived: sum of 3 quarters · filed 2022-03-01 | -$39.74M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$19.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$30.44M derived: sum of 2 quarters · filed 2020-11-05 | -$36.66M 10-Q · filed 2020-11-05 | -$75.49M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | -$10.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$16.82M 10-Q · filed 2020-08-10 | -$55.65M derived: sum of 3 quarters · filed 2021-02-25 | -$63.63M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$6.22M 10-Q · filed 2020-05-05 | -$45.05M derived: sum of 2 quarters · filed 2021-02-25 | -$53.03M derived: sum of 3 quarters · filed 2021-02-25 | -$63.76M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$38.83M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$46.81M derived: sum of 2 quarters · filed 2021-02-25 | -$57.54M derived: sum of 3 quarters · filed 2021-02-25 | -$66.94M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$7.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$18.71M derived: sum of 2 quarters · filed 2019-11-12 | -$28.10M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$10.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$20.12M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | -$9.39M 10-Q · filed 2019-05-09 | |||
| 2017-12-31 | -$17.66M 10-K · filed 2020-03-12 | |||
| 2016-12-31 | $197.29M 10-K · filed 2019-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |